leisure time -WSS

leisure time

author：hotspot 2025-10-02 22:40:17 - browse：7773

Biotech startup Generate Biomedicines, which uses artificial intelligence to find new drugs, raised $273 million in a Series C funding round from investors including pharma company Amgen and the VC arm of AI giant NVIDIA.

Generate was founded in 2018 by venture-creation firm Flagship Pioneering to use machine learning algorithms to identify antibodies, peptides, cell therapies, and other medicines. It launched its first clinical trial in July for a Covid monoclonal antibody, and is working on starting another clinical trial for an asthma treatment.

The biotech, which is based in Somerville, Mass., has big plans for the next couple of years: It has another 15 drug candidates in the works and plans to introduce 10 more annually, CEO Mike Nally told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Some top drug companies are starting to take action on climate

hotspot

WSS

Experts study whether long Covid risk adds up with each reinfection

Medical student insurance fails on mental health care coverage

Thermo Fisher plant for manufacturing gene therapies to expand

With Roe v Wade overturned, abortion providers work to adapt

The biotech scorecard for Q4: 16 stock

New oral drug delivery patch is modeled after octopus tentacles

focus

leisure time

hotspot

Medicare details structure of new drug price negotiation program

Microbiome research is starting to find links to chronic diseases

Virginia high school admissions case could be legal follow

It's been 20 years since Dolly the sheep. Where's my clone?

ChatGPT in medicine: STAT answers readers' burning questions

The stability of $0 premiums in Medicare Advantage

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

BioMarin wins approval for gene therapy to treat hemophilia A

WHO recommends second malaria vaccine

hotspot

Medicare innovation center doesn’t save money, experts say

Readout LOUD podcast: possible new ALS drug, artificial wombs

Microbiome research is starting to find links to chronic diseases

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Lasker Awards 2023: Winners in biomedical research

What will Novo Nordisk's VC do with its influx of cash?

knowledge

hotspot

entertainment

focus